Department of Chemistry
Professor of Chemistry
Ph.D. Oregon Health Sciences University, 1982
(Malaria Pharmacology, Functional Genomics)
(206) 221-6069
or (206) 616-5179
Email: rathod@chem.washington.edu
Malaria is a major cause of morbidity and mortality in the world, with about 2 million deaths and over 500 million infections per year. With the emergence of resistance against traditional drugs, there is an urgent need for new, affordable medicines against Plasmodium. Faithful, disciplined application of chemical principles to increasingly sophisticated understanding of biology can lead to new drug targets, candidate drugs, and can help reveal new principles in biology.
TARGETING HIGH-VALUE PYRIMIDINE BIOSYNTHESIS ENZYMES with selectivity by starting with host-parasite protein differences at the active-site, by appropriate pro-drugs, by supplementing non-selective antifolates with rescuing nutrients that only the host can use, or by disrupting unique protein-protein interactions. The Rathod lab targets malarial:
Deng X, Gujjar R, El Mazouni F, Kaminsky W, Malmquist NA, Goldsmith EJ, Rathod PK, Phillips MA. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J Biol Chem. 2009 Jul 28. [Epub ahead of print] PMID: 19640844
Herricks T, Antia M, and Rathod PK. 2009 “Deformability limits of Plasmodium falciparum-infected red blood cells”, Cell Microbiol. 2009 Apr 30. [Epub ahead of print] PMID: 19438513
Gujjar, R., Marwaha, A., El Mazouni, F., White, J., White, K. L., Creason, S., Shackleford, D. M., Baldwin, J., Charman, W. N., Buckner, F.S., Charman, S., Rathod, P.K. and Phillips, M.A. 2009. “Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with anti-malarial activity in mice”, J. Med. Chem. 52 (7), 1864-1872 PMID: 19296651
Grand Challenges Explorations Award, B&MG Foundation
Co-Chair, Molecular Parasitology Meeting, Woods Hole, MA
Co-Chair, Keystone Meeting, Parasite Drug Development